Pharmacological Approaches to Stuttering Treatment: Reply to Meline and Harn (2008) Purpose To address questions raised by T. Meline and W. E. Harn (2008)  in their critique of our previous article (A. K. Bothe, J. H. Davidow, R. E. Bramlett, D. M. Franic, & R. J. Ingham, 2006). Method Additional information is provided to address several issues raised by ... Letter to the Editor
Letter to the Editor  |   February 01, 2008
Pharmacological Approaches to Stuttering Treatment: Reply to Meline and Harn (2008)
 
Author Affiliations & Notes
  • Anne K. Bothe
    The University of Georgia, Athens
  • Duska M. Franic
    The University of Georgia, Athens
  • Roger J. Ingham
    University of California, Santa Barbara
  • Jason H. Davidow
    Hofstra University, Hempstead, NY
  • Contact author: Anne K. Bothe, Department of Communication Sciences and Special Education, 516 Aderhold Hall, The University of Georgia, Athens, GA 30602. E-mail: abothe@uga.edu.
Article Information
Speech, Voice & Prosodic Disorders / Fluency Disorders / Letters to the Editor
Letter to the Editor   |   February 01, 2008
Pharmacological Approaches to Stuttering Treatment: Reply to Meline and Harn (2008)
American Journal of Speech-Language Pathology, February 2008, Vol. 17, 98-101. doi:10.1044/1058-0360(2008/010)
History: Received September 11, 2007 , Accepted October 31, 2007
 
American Journal of Speech-Language Pathology, February 2008, Vol. 17, 98-101. doi:10.1044/1058-0360(2008/010)
History: Received September 11, 2007; Accepted October 31, 2007

Purpose To address questions raised by T. Meline and W. E. Harn (2008)  in their critique of our previous article (A. K. Bothe, J. H. Davidow, R. E. Bramlett, D. M. Franic, & R. J. Ingham, 2006).

Method Additional information is provided to address several issues raised by Meline and Harn.

Results and Conclusions Our previous systematic review omitted 1 relevant article about the use of olanzapine in stuttering, but the minimal effectiveness and the known serious side effects of this drug limit the implications of this omission. While we do not agree with many of Meline and Harn’s critiques of our review, we do agree with them that several larger points raise interesting questions about the structure, analysis, and usefulness of literature reviews in stuttering and in other areas. Fundamentally, we reassert our agreement with Meline and Harn that there is insufficient evidence to support the use of existing pharmacological agents in the treatment of stuttering.

Order a Subscription
Pay Per View
Entire American Journal of Speech-Language Pathology content & archive
24-hour access
This Article
24-hour access